MedTrace Logo

Evaluation of the High Frequency Digit Triplet Test in Cystic Fibrosis

NCT02252601 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 388

Last updated 2016-04-12

No results posted yet for this study

Summary

The purpose of this study is to find out whether the High Frequency Digit Triplet test can be used to screen patients with cystic fibrosis for hearing loss in conditions of health and pulmonary exacerbation. It is also designed to find out the youngest age at which a child can perform the test, the prevalence of hearing loss in a CF population and the prevalence of genetic mutations known to be associated with hearing loss in the same population.

Conditions

Interventions

OTHER

HFDT test

OTHER

Pure tone Audiogram

Sponsors & Collaborators

  • Nottingham University Hospitals NHS Trust

    collaborator OTHER

  • Heart of England NHS Trust

    collaborator OTHER

  • Birmingham Women's and Children's NHS Foundation Trust

    collaborator OTHER

  • University of Nottingham

    lead OTHER

Principal Investigators

  • Alan Smyth, MD · The University of Nottingham

Study Design

Allocation
NON_RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
5 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2018-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02252601 on ClinicalTrials.gov